Title: Efficacy of AS vs SOX regimen as first-line chemotherapy for gastric cancer patients with
peritoneal metastasis: a real-world study
Version: 2 Date: 26 Apr 2022
Reviewer's report:
Major point
ATTRACTION-4 trial and CheckMate 649 trial revealed that Nivolumab plus chemotherapy
improves OS or PFS in patients with advanced gastric adenocarcimoma as compared to
chemotherapy alone. Please relate these important findings to your results in the Discussion
section.
Minor points
Please grade the adverse events in Table 3 as you described in the methods section “Adverse
event (AEs) were graded according to the Common Terminology Criteria for Adverse Events
version 5.0”.
Please provide which factors do you use to perform the propensity score matching in the Methods
section.
According to the Results section, some patients seem to be treated with immune checkpoint
inhibitors or trastuzumab as a first line chemotherapy. If so, Please write down these regimens
in the Methods section.
The median OS in the AS group after PSM described in the main text does not match the number
described in Table 2. Moreover, the median OS in the SOX group (non-intestinal) after PSM
described in the main text does not match the number described in Table 2. Please correct these
numbers.
The numbers of OS and PFS in Lauren mixed type described in the main text exactly match the
numbers described as those in Lauren diffuse type in Table 2. Please check these descriptions
again and correct if necessary.
Title: Efficacy of AS vs SOX regimen as first-line chemotherapy for gastric cancer patients with
peritoneal metastasis: a real-world study
Version: 2 Date: 26 Apr 2022
Reviewer's report:
Major point
ATTRACTION-4 trial and CheckMate 649 trial revealed that Nivolumab plus chemotherapy
improves OS or PFS in patients with advanced gastric adenocarcimoma as compared to
chemotherapy alone. Please relate these important findings to your results in the Discussion
section.
Minor points
Please grade the adverse events in Table 3 as you described in the methods section “Adverse
event (AEs) were graded according to the Common Terminology Criteria for Adverse Events
version 5.0”.
Please provide which factors do you use to perform the propensity score matching in the Methods
section.
According to the Results section, some patients seem to be treated with immune checkpoint
inhibitors or trastuzumab as a first line chemotherapy. If so, Please write down these regimens
in the Methods section.
The median OS in the AS group after PSM described in the main text does not match the number
described in Table 2. Moreover, the median OS in the SOX group (non-intestinal) after PSM
described in the main text does not match the number described in Table 2. Please correct these
numbers.
The numbers of OS and PFS in Lauren mixed type described in the main text exactly match the
numbers described as those in Lauren diffuse type in Table 2. Please check these descriptions
again and correct if necessary.
Please review this paper.
user
Title: Efficacy of AS vs SOX regimen as first-line chemotherapy for gastric cancer patients with
peritoneal metastasis: a real-world study
Version: 2 Date: 26 Apr 2022
Reviewer's report:
Major point
ATTRACTION-4 trial and CheckMate 649 trial revealed that Nivolumab plus chemotherapy
improves OS or PFS in patients with advanced gastric adenocarcimoma as compared to
chemotherapy alone. Please relate these important findings to your results in the Discussion
section.
Minor points
Please grade the adverse events in Table 3 as you described in the methods section “Adverse
event (AEs) were graded according to the Common Terminology Criteria for Adverse Events
version 5.0”.
Please provide which factors do you use to perform the propensity score matching in the Methods
section.
According to the Results section, some patients seem to be treated with immune checkpoint
inhibitors or trastuzumab as a first line chemotherapy. If so, Please write down these regimens
in the Methods section.
The median OS in the AS group after PSM described in the main text does not match the number
described in Table 2. Moreover, the median OS in the SOX group (non-intestinal) after PSM
described in the main text does not match the number described in Table 2. Please correct these
numbers.
The numbers of OS and PFS in Lauren mixed type described in the main text exactly match the
numbers described as those in Lauren diffuse type in Table 2. Please check these descriptions
again and correct if necessary.
assistant